Treatment of dyskinesias

• US 3,983,234 A
• Filed: 06/25/1975
• Issued: 09/28/1976
• Est. Priority Date: 07/04/1974
• Status: Expired due to Term

• Current Assignee: Fidelity Union Trust Co (Wells Fargo & Company)
• Original Assignee: Sandoz Inc. (Novartis Ag)
• Inventors: Sayers, Anthony Campbell
• Primary Examiner(s): Friedman, Stanley J.
• Application Number:
  US05/590,146
• Time in Patent Office: 461 Days
• Field of Search: 424/319, 424/250
• US Class Current: 514/220
• CPC Class Codes: A61K 31/5513 1,4-Benzodiazepines, e.g. diazepam or clozapine

Abstract

Clozapine is useful in the treatment of dyskinesias.

Claims

1. A method of treating dyskinesias in animals induced by the action of a dopaminergic substance useful in the treatment of Parkinson'"'"'s desease on hypersensitive dopamine receptors, without blocking the receptors, which comprises administering 0.4 to 80 milligrams per kilogram of animal body weight of clozapine to an animal in need of such treatment.

2. A method according to claim 1, wherein the dopaminergic substance is DOPA.

3. A method of treating animals suffering from Parkinson'"'"'s disease comprising administering to an animal in need of such treatment a therapeutically effective amount of a dopaminergic substance useful in treating Parkinson'"'"'s desease and concomitantly 0.4 to 80 milligrams per kilogram of animal body weight per day of clozapine to suppress dyskinesias induced by administration of the dopaminergic substance.

4. A method according to claim 3, wherein the daily dosage of clozapine is from 25 to 200 milligrams.

5. A method according to claim 3, wherein clozapine is orally administered at a unit dose of 6 to 100 milligrams.